Zelluna Immunotherapy is Drug Discovery in Norway that focus on based cancer immunotherapy business. Founded in 2016. They cover business area such as operator, t-cell receptor, (TCR, base cancer immunotherapy, a portfolio, tumor-specific tcr, nk cell, cancer response, safe, efficient and durable, enable patient, efficient treatment, their require treatment, advanced technology.
2016
( 8 years old in 2024 )
Based Cancer Immunotherapy
-
Oslo Cancer Cluster Innovation Park
Ullernchausséen 64
0379 Oslo
Norway
Private
operatort-cell receptor(TCRbase cancer immunotherapya portfoliotumor-specific tcrnk cellcancer responsesafe, efficient and durable, enable patientefficient treatmenttheir require treatmentadvanced technology
* We use standard office opening hours in near Zelluna Immunotherapy's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Zelluna Immunotherapy is Drug Discovery business from Norway that founded in 2016 (8 years old in 2024), Zelluna Immunotherapy business is focusing on Based Cancer Immunotherapy.
Zelluna Immunotherapy headquarter office and corporate office address is located in Oslo Cancer Cluster Innovation Park Ullernchausséen 64 0379 Oslo Norway.
Zelluna Immunotherapy was founded in Norway.
In 2024, Zelluna Immunotherapy is currently focus on based cancer immunotherapy sector.
Above is snippet of Google Trends for "based cancer immunotherapy" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Zelluna Immunotherapy, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
